Economic aspects of bladder cancer: What are the benefits and costs?

World Journal of Urology

Volumn 27, Issue 3, 2009, Pages 295-300

  Sievert, K D ^a   Amend, B ^a   Nagele, U ^a   Schilling, D ^a   Bedke, J ^a   Horstmann, M ^a   Hennenlotter, J ^a   Kruck, S ^a   Stenzl, A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Diagnosis and treatment; Economic and cost considerations; Fluorescence cystoscopy; Hexvix; Imaging technology; Intravesical chemotherapy; NIMBC; PDD; TURB

Indexed keywords

ARTICLE; BLADDER TUMOR; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; HUMAN;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 67349137406     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0395-z     Document Type: Article

References (40)

1. Miller BA, Kolonel LN, Bernstein L et al (1996) Racial/ethnic patterns of cancer in the United States 1988-1992, National Cancer Institute. NIH Pub. No. 96-4104, Bethesda
2. Ferlay J, Parkin DM, Pisani P (2001) GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. IARC Press, Lyon
3. American Cancer Society Cancer facts & figures. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed 20 March 2007
4. Han M, Schoenberg MP (2000) The use of molecular diagnostics in bladder cancer. Urol Oncol 5:87-92. doi: 10.1016/S1078-1439(99)00052-6
5. Botteman MF, Pashos CL, Redaelli A et al (2003) The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21:1315-1330. doi: 10.2165/00019053-200321180-00003
6. Ruttenberg R, Powers M (1986) Economics of notification and medical screening for high-risk workers. J Occup Med 28:757-764. doi: 10.1097/ 00043764-198608000-00041
7. Brown ML, Riley GF, Schussler N et al (2002) Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40:IV-104-IV-117. doi: 10.1097/00005650-200208001-00014
8. Sangar VK, Ragavan N, Matanhelia SS et al (2005) The economic consequences of prostate and bladder cancer in the UK. BJU Int 95:59-63. doi: 10.1111/j.1464-410X.2005.05249.x
9. Herr HW (2000) Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 163:60-61. doi: 10.1016/S0022-5347(05)67972-4 discussion 61-2
10. Marchetti A, Wang L, Magar R et al (2000) Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin. Clin Ther 22:422-438. doi: 10.1016/S0149-2918(00)89011-6
11. Stenzl A, Roessler W, Fradet Y et al (2009) Hexvix® fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: A multicentre, prospective, randomized study. Abstract EAU Congress 2009 Stockholm
12. Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 107:982-990. doi: 10.1002/cncr.22084
13. Berookhim BM, Sethi AS, Wen CC et al (2008) A cost comparison of the diagnostic modalities used in the detection of urothelial carcinoma in patients undergoing evaluation for hematuria. UIJ 1 (in press). doi: 10.3834/uij.1939-4810.2008.12.01
14. Konety BR, Joyce GF, Wise M (2007) Bladder and upper tract urothelial cancer. J Urol 177:1636-1645. doi: 10.1016/j.juro.2007.01.055
15. Grasso M (2008) Bladder cancer: A major public health issue. Eur Urol Suppl 7:510-515. doi: 10.1016/j.eursup.2008.04.001
16. Uchida A, Yonou H, Hayashi E et al (2007) Intravesical instillation of bacille Calmette-Guerin for superficial bladder cancer: cost-effectiveness analysis. Urology 69:275-279. doi: 10.1016/ j.urology.2006.10.017
17. Babjuk M, Oosterlinck W, Sylvester R et al (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303-314. doi: 10.1016/j.eururo.2008.04.051
18. Daniltchenko DI, Riedl CR, Sachs MD et al (2005) Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174:2129-2133. doi: 10.1097/01.ju.0000181814.73466.14 (discussion 2133)
19. Burger M, Zaak D, Stief CG et al (2007) Photodynamic diagnostics and noninvasive bladder cancer: Is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52:142-147. doi: 10.1016/j.eururo.2007.01.064
20. Stenzl A, Hoeltl L, Bartsch G (2001) Fluorescence assisted transurethral resection of bladder tumours: Is it cost effective? Eur Urol 39:31. doi: 10.1159/000052565
21. Denzinger S, Burger M, Walter B et al (2007) Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69:675-679. doi: 10.1016/ j.urology.2006.12.023
22. Kruck S, Horstmann M, Hennenlotter J, et al (2009) Virtual transurethral bladder resection training for urologists. Abstract AUA Meeting Chicago
23. Zaak D, Wieland WF, Stief CG et al (2008) Routine use of photodynamic diagnosis of bladder cancer. Pract Econ Issues Eur Urol Suppl 7:536-541. doi: 10.1016/j.eursup.2008.04.005
24. Malmstrom PU, Hedelin H (2006) Potential cost savings through the use of fluorescence cystoscopy in superficial bladder cancer: Development of an economic model. Urology 68(Suppl 1):40-41. doi: 10.1016/ j.urology.2006.08.128
25. Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 171:2186-2190. doi: 10.1097/01.ju.0000125486.92260.b2 quiz 2435
26. Tolley DA, Parmar MK, Grigor KM et al (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155:1233-1238. doi: 10.1016/S0022-5347(01)66226-8
27. Kaasinen E, Rintala E, Hellstrom P et al (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42:167-174. doi: 10.1016/S0302-2838(02)00260-9
28. Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90-95. doi: 10.1016/S0022-5347(05)64043-8
29. Losa A, Hurle R, Lembo A (2000) Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: Long-term results. J Urol 163:68-71. doi: 10.1016/S0022-5347(05)67974-8 (discussion 71-2)
30. Young MJ, Soloway MS (1998) Office evaluation and management of bladder neoplasms. Urol Clin North Am 25:603-611. doi: 10.1016/ S0094-0143(05)70051-3
31. Kilbridge KL, Kantoff PW, Loughlin KR (1997) Is bacillus calmette-guerin (BCG) immunotherapy cost-effective in recurrent high grade transitional cell cancer (TCC)? J Urol 157(4) (Suppl):214. Abstract
32. Smith JA Jr, Labasky RF, Cockett AT et al (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162:1697-1701. doi: 10.1016/S0022-5347(05)68208-0
33. Cooksley CD, Avritscher EB, Grossman HB et al (2008) Clinical model of cost of bladder cancer in the elderly. Urology 71:519-525. doi: 10.1016/ j.urology.2007.10.056
34. Konety BR, Allareddy V (2007) Influence of post-cystectomy complications on cost and subsequent outcome. J Urol 177:280-287. doi: 10.1016/ j.juro.2006.08.074 (discussion 287)
35. Avritscher EB, Cooksley CD, Grossman HB et al (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68:549-553. doi: 10.1016/j.urology.2006.03.062
36. Langa KM, Fendrick AM, Chernew ME et al (2004) Out-of-pocket health-care expenditures among older Americans with cancer. Value Health 7:186-194. doi: 10.1111/j.1524-4733.2004.72334.x
37. USA Today/Kaiser Family Foundation/Harvard School of Public Health Health Care Costs Survey Summary and Chartpack (publication No. 7371) (2005) The Henry J. Kaiser Family Foundation, Menlo Park (CA). Available at: http://www.kff.org/newsmedia/7371.cfm. Accessed 20 March 2007
38. Yabroff KR, Davis WW, Lamont EB et al (2007) Patient time costs associated with cancer care. J Natl Cancer Inst 99:14-23
39. The estimated NCI investment is based on funding associated with a broad range of peer-reviewed scientific activities. For additional information on research planning and budgeting at the National Institutes of Health. Available at: http://www.nih.gov/about/
40. D'Hallewin MA, Bezdetnaya L, Guillemin F (2002) Fluorescence detection of bladder cancer: A review. Eur Urol 42:417-425. doi: 10.1016/ S0302-2838(02)00402-5